rs2236212 — ELOVL2

ELOVL2 — The Final Step in DHA Synthesis

Most people know that omega-3 fatty acids protect the heart and brain, but far fewer know that the body's ability to make its own DHA from dietary precursors varies significantly by genetics. The ELOVL2 gene encodes elongase-2¹¹ elongase-2
An enzyme in the endoplasmic reticulum that extends the carbon chain of long-chain polyunsaturated fatty acids by two carbon units per catalytic cycle, the enzyme responsible for the final elongation steps in the omega-3 pathway: converting EPA (20:5) to DPA²² DPA
Docosapentaenoic acid (22:5 n-3) — an intermediate omega-3 that accumulates when the final step to DHA is impaired and DPA to DHA³³ DHA
Docosahexaenoic acid (22:6 n-3) — the dominant omega-3 in brain and retinal tissue, required for synaptic plasticity, visual function, and anti-inflammatory signaling. The rs2236212 variant, located in an intron of the ELOVL2 gene, is associated with reduced elongase activity and has measurable effects on circulating DHA levels, liver fat accumulation, and the magnitude of response to omega-3 supplementation.

The Mechanism

ELOVL2 is most highly expressed in the liver, where it catalyzes two sequential elongation reactions: EPA → DPA (24:5), then DPA → TPA (24:6), which is then desaturated and chain-shortened to DHA by the enzyme FADS2. The rs2236212 C allele is an intronic variant that does not alter the amino acid sequence of the protein, but appears to reduce the transcriptional output or splicing efficiency of the ELOVL2 gene, resulting in lower effective elongase activity. Maguolo and colleagues⁴⁴ Maguolo and colleagues
Maguolo A et al. Influence of genetic variants in FADS2 and ELOVL2 genes on BMI and PUFAs homeostasis in children and adolescents with obesity. Int J Obes, 2021 demonstrated this directly in a cohort of 1,649 obese Italian children: the rs2236212 C allele was significantly associated with reduced enzymatic elongation activity (p = 0.048), confirming that the genotype has a measurable functional consequence.

The downstream result is that C-allele carriers convert EPA to DHA less efficiently, causing EPA and DPA to accumulate at slightly higher levels while DHA production is blunted. This creates a scenario where baseline plasma DHA may be lower, but the precursor EPA is more readily available — which explains the paradox seen in supplementation studies.

The Evidence

The most directly informative study is by Alsaleh and colleagues⁵⁵ Alsaleh and colleagues
Alsaleh A et al. ELOVL2 gene polymorphisms are associated with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after fish oil supplement. Genes Nutr, 2014 who randomized 367 subjects to different fish oil doses. At the highest dose (1.8 g/day EPA+DHA), minor C-allele carriers showed approximately 30% higher plasma EPA and 9% higher DHA compared to GG homozygotes, with a highly significant genotype × treatment interaction (p < 0.0001 for EPA; p = 0.004 for DHA). At baseline, however, C-allele carriers had lower DHA proportions. This pattern — lower baseline DHA, larger supplementation response — is the hallmark of impaired endogenous elongation that can be partially rescued by exogenous DHA supply.

Large-scale population genetics supports this. The CHARGE Consortium meta-analysis⁶⁶ CHARGE Consortium meta-analysis
Lemaitre RN et al. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet, 2011 of 8,866 European adults found that ELOVL2 minor alleles were associated with higher EPA (p = 2×10⁻¹²) and DPA (p = 1×10⁻⁴³) but lower DHA (p = 1×10⁻¹⁵) in plasma phospholipids — exactly the pattern expected from a reduction in the EPA→DPA→DHA elongation cascade.

Beyond fatty acid composition, the rs2236212 C allele has also been linked to metabolic consequences of impaired DHA synthesis. In a cohort of 514 obese children, Zusi and colleagues⁷⁷ Zusi and colleagues
Zusi C et al. Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents. Dig Liver Dis, 2019 found that rs2236212 was independently associated with a 34% higher odds of nonalcoholic fatty liver disease (NAFLD; OR = 1.34, p = 0.047). This is biologically plausible: DHA regulates hepatic lipid metabolism and reduces de novo lipogenesis; impaired DHA synthesis could contribute to hepatic fat accumulation.

Practical Implications

The key take-away for C-allele carriers — particularly CC homozygotes — is that the body's endogenous DHA production is constrained. This means dietary EPA (from flaxseed, chia seeds, walnuts) is a poor substitute for preformed DHA, because the elongation step that would convert EPA to DHA is exactly what is compromised. Preformed DHA from marine sources bypasses this bottleneck entirely.

The Alsaleh supplementation data also suggests that C-allele carriers are not unresponsive to omega-3s — quite the opposite. They appear to derive a larger relative increase in EPA and DHA from supplementation, meaning preformed DHA supplementation is both necessary and effective for this genotype.

Interactions

ELOVL2 functions downstream of the FADS desaturases in the omega-3 pathway. The FADS1 and FADS2 enzymes (encoded by variants including rs174547 and rs174537) perform the preceding desaturation steps, converting alpha-linolenic acid (ALA) to EPA. C-allele carriers at rs2236212 who also carry low-activity FADS variants face a compounded impairment across multiple steps of the omega-3 synthesis pathway. For these individuals, reliance on plant-based ALA is doubly ineffective — both the FADS desaturation step and the ELOVL2 elongation step are compromised. The ELOVL2 rs953413 variant is in linkage disequilibrium with rs2236212 in European populations and has been studied independently in relation to sex-specific differences in DHA response to EPA supplementation.